Frank Zenke

Company: FoRx Therapeutics

Job title: Chief Scientific Officer

Seminars:

FORX-428: A Novel, Potent PARG Inhibitor Demonstrating Strong Anti- Tumor Activity in Preclinical Cancer Models 8:00 am

Reviewing the rationale for targeting PARG to selectively treat cancers with deficiencies in DNA repair Assessing the characteristics of FORX-428, emphasizing its potency, selectivity, and promising efficacy in various cancer models Uncovering the for advancing FORX-428 to clinical trials for cancer therapyRead more

day: Day Two